Comparison of Intravenous with Oral Busulfan in Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Regimens for Pediatric Acute Leukemia

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 12, 2013, Pages 1690-1694

  Kato, Motohiro ^a,b   Takahashi, Yoshiyuki ^c   Tomizawa, Daisuke ^d   Okamoto, Yasuhiro ^e   Inagaki, Jiro ^f   Koh, Katsuyoshi ^b   Ogawa, Atsushi ^g   Okada, Keiko ^h   Cho, Yuko ⁱ   Takita, Junko ^a   Goto, Hiroaki ^j   Sakamaki, Hisashi ^k   Yabe, Hiromasa ^l   Kawa, Keisei ^m   Suzuki, Ritsuro ⁿ   Kudo, Kazuko ^o   Kato, Koji ^p  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g NIIGATA CANCER CENTER HOSPITAL   (Japan)

^h OSAKA CITY GENERAL HOSPITAL   (Japan)

ⁱ HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^j KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^k TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^l TOKAI UNIVERSITY   (Japan)

^m Japanese Red Cross Kinki Block Blood Center   (Japan)

ⁿ NAGOYA UNIVERSITY   (Japan)

^o SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^p JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

more..

Author keywords

Acute leukemia; Busulfan; Children

Indexed keywords

BUSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; INFANT; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD;

ACUTE LEUKEMIA; BUSULFAN; CHILDREN;

ACUTE DISEASE; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA; MALE; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

EID: 84887555975     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.09.012     Document Type: Article

References (24)

1. Santos G.W., Tutschka P.J., Brookmeyer R., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. NEngl J Med 1983, 309:1347-1353.
2. Hassan M., Ljungman P., Bolme P., et al. Busulfan bioavailability. Blood 1994, 84:2144-2150.
3. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
4. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000, 25:925-930.
5. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995, 16:31-42.
6. Strahm B., Nollke P., Zecca M., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011, 25:455-462.
7. Michel G., Gluckman E., Esperou-Bourdeau H., et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation-a report from the Societe Francaise de Greffe de Moelle. JClin Oncol 1994, 12:1217-1222.
8. Schiltmeyer B., Klingebiel T., Schwab M., et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol 2003, 52:209-216.
9. Tran H.T., Madden T., Petropoulos D., et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000, 26:463-470.
10. Bleyzac N., Souillet G., Magron P., et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001, 28:743-751.
11. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001, 28:1013-1018.
12. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000, 6:548-554.
13. Kim S.E., Lee J.H., Choi S.J., et al. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. Haematologica 2005, 90:285-286.
14. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002, 8:493-500.
15. Aggarwal C., Gupta S., Vaughan W.P., et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006, 12:770-777.
16. Sobecks R.M., Rybicki L., Yurch M., et al. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS. Bone Marrow Transplant 2012, 47:633-638.
17. Dean R.M., Pohlman B., Sweetenham J.W., et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol 2010, 148:226-234.
18. Schechter T., Finkelstein Y., Doyle J., et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:307-314.
19. Zwaveling J., Bredius R.G., Cremers S.C., et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005, 35:17-23.
20. Bartelink I.H., Bredius R.G., Ververs T.T., et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:88-98.
21. Atsuta Y., Suzuki R., Yoshimi A., et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007, 86:269-274.
22. Hartman A.R., Williams S.F., Dillon J.J. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998, 22:439-443.
23. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201-1207.
24. Michel G., Valteau-Couanet D., Gentet J.C., et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer 2012, 58:90-97.